Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Releases Earnings Results, Beats Expectations By $0.06 EPS

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued its quarterly earnings data on Tuesday. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.06, Zacks reports. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%.

Bayer Aktiengesellschaft Stock Down 2.3%

Bayer Aktiengesellschaft stock opened at $13.57 on Tuesday. The company has a market capitalization of $53.33 billion, a P/E ratio of -21.20, a PEG ratio of 4.46 and a beta of 0.55. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.70 and a current ratio of 1.05. Bayer Aktiengesellschaft has a fifty-two week low of $7.19 and a fifty-two week high of $15.23. The stock has a 50-day simple moving average of $12.36 and a 200-day simple moving average of $12.08.

Analyst Upgrades and Downgrades

BAYRY has been the subject of a number of research reports. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. Finally, Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Bayer Aktiengesellschaft currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.